
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4118329/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats. Cellular and Molecular Neurobiology, 2020, 40, 215-228.	1.7	10
2	Study of aversive and p38 mapk-inhibitory properties of kappa-agonist with analgesic activity – compound RU-1205. Research Results in Pharmacology, 2020, 6, 59-65.	0.1	1
3	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Molecular Psychiatry, 2019, 24, 1099-1111.	4.1	11
4	Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV,the, 2019, 6, e221-e229.	2.1	13
5	Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. Psychopharmacology, 2018, 235, 1955-1965.	1.5	23
6	Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia. Drug and Alcohol Dependence, 2017, 172, 60-65.	1.6	5
7	mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?. Psychopharmacology, 2017, 234, 1333-1345.	1.5	5
8	Pain and Risk Behaviors Among HIV-Infected Persons in St. Petersburg, Russia. AIDS and Behavior, 2017, 21, 1775-1781.	1.4	4
9	Antagonist Treatment for Opioid Dependence: Promise and Hurdles. Current Treatment Options in Psychiatry, 2017, 4, 221-230.	0.7	1
10	Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. American Journal of Drug and Alcohol Abuse, 2016, 42, 614-620.	1.1	77
11	Morphine-induced Straub tail reaction in mice treated with serotonergic compounds. European Journal of Pharmacology, 2016, 791, 1-7.	1.7	14
12	Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 457-466.	1.4	1
13	Antagonist Models for Relapse Prevention and Reducing HIV Risk. Journal of Neurolmmune Pharmacology, 2016, 11, 401-407.	2.1	2
14	Determination of Buprenorphine and Naloxone in Patient Blood Plasma Using HPLC-MS. Pharmaceutical Chemistry Journal, 2015, 48, 690-695.	0.3	6
15	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. AIDS and Behavior, 2015, 19, 1089-1097.	1.4	9
16	Depression, substance use, viral load, and CD4+ count among patients who continued or left antiretroviral therapy for HIV in St. Petersburg, Russian Federation. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 86-92.	0.6	28
17	<scp>HERMITAGE</scp> —a randomized controlled trial to reduce sexually transmitted infections and <scp>HIV</scp> risk behaviors among <scp>HIV</scp> â€infected <scp>R</scp> ussian drinkers. Addiction, 2015, 110, 80-90.	1.7	35
18	Use of Different Drug Formulations of Opioid Antagonist (Naltrexone) to Treat Opioid Dependence in		1

2

EDWIN E ZVARTAU

#	Article	IF	CITATIONS
19	Effects of Catechol-O-Methyltransferase Deficiency on the Reinforcing Effects of Cocaine (an) Tj ETQq1 1 0.784	314 rgBT ,	Overlock 10
20	Naltrexone with or without guanfacine for preventing relapse to opiate addiction in StPetersburg, Russia. Drug and Alcohol Dependence, 2013, 132, 674-680.	1.6	34
21	ls cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. Drug and Alcohol Dependence, 2013, 132, 74-80.	1.6	20
22	Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence. Archives of General Psychiatry, 2012, 69, 973.	13.8	115
23	Double jeopardy–drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial. Substance Abuse Treatment, Prevention, and Policy, 2012, 7, 1.	1.0	61
24	Differences in the consumption rates and regulatory barriers to the accessibility of strong opioid analgesics in Israel and St. Petersburg. European Journal of Clinical Pharmacology, 2012, 68, 89-95.	0.8	12
25	Effects of alcohol withdrawal on cardiovascular system. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 550-553.	2.5	12
26	A sequencingâ€based survey of functional <i>APAF1</i> alleles in a large sample of individuals with affective illness and population controls. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 332-335.	1.1	0
27	Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available. Current Psychiatry Reports, 2010, 12, 448-453.	2.1	95
28	Interaction of Blockers of Ionotropic NMDA Receptors and Metabotropic Glutamate Receptors in a Working Memory Test in Rats. Neuroscience and Behavioral Physiology, 2010, 40, 807-811.	0.2	5
29	Nicotine exposure throughout early development promotes nicotine self-administration in adolescent mice and induces long-lasting behavioural changes. European Journal of Pharmacology, 2010, 640, 87-93.	1.7	26
30	Estradiol lowers intracranial self-stimulation thresholds and enhances cocaine facilitation of intracranial self-stimulation in rats. Hormones and Behavior, 2010, 58, 827-834.	1.0	19
31	Addiction treatment in Russia. Lancet, The, 2010, 376, 1145.	6.3	9
32	Binge Drinking and Unsafe Sex: A Study of Narcology Hospital Patients from St. Petersburg, Russia. Substance Abuse, 2009, 30, 213-222.	1.1	7
33	Infectious Diseases And Medical Complications Of Drug Abuse- Part 1: Naltrexone treatment and HIV risk reduction for heroin addiction: 10-years Penn-Pavlov experience. Canadian Journal of Addiction, 2009, 1, 27-28.	0.2	0
34	Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology, 2008, 196, 211-220.	1.5	42
35	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. AIDS and Behavior, 2008, 12, 662-669.	1.4	11
36	Mitigating risky sexual behaviors among Russian narcology hospital patients: the PREVENT (Partnership to Reduce the Epidemic Via Engagement in Narcology Treatment) randomized controlled trial. Addiction, 2008, 103, 1474-1483.	1.7	19

#	Article	IF	CITATIONS
37	Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. European Journal of Pharmacology, 2008, 591, 164-170.	1.7	11
38	Endogenous bufadienolide mediates pressor response to ethanol withdrawal in rats. European Neuropsychopharmacology, 2008, 18, 74-77.	0.3	7
39	Effects of Verapamil, an Antagonist of L-Type Calcium Channels, on Cardiovascular Symptoms in Alcohol Withdrawal. Neuropsychobiology, 2008, 58, 123-127.	0.9	5
40	Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients. American Journal of Psychiatry, 2007, 164, 519-523.	4.0	106
41	mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology, 2007, 52, 263-269.	2.0	91
42	Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug and Alcohol Dependence, 2007, 90, 25-38.	1.6	86
43	Cardiovascular effects of propranolol in patients with alcohol dependence during withdrawal. International Journal of Psychophysiology, 2007, 66, 225-230.	0.5	3
44	Mutation screen of theGAD2 gene and association study of alcoholism in three populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 183-192.	1.1	23
45	Overcoming opioid blockade from depot naltrexone (Prodetoxon®). Addiction, 2007, 102, 1164-1165.	1.7	28
46	Alcohol Use in Pregnant and Nonpregnant Russian Women. Alcoholism: Clinical and Experimental Research, 2007, 31, 299-307.	1.4	42
47	Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136008-???.	1.4	103
48	Gender Differences in Neurocognitive Functioning Among Alcohol-Dependent Russian Patients. Alcoholism: Clinical and Experimental Research, 2007, 31, 745-754.	1.4	38
49	Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2006, 31, 319-328.	1.5	95
50	Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists. Behavioural Pharmacology, 2006, 17, 295-302.	0.8	12
51	A highly selective κ-opioid receptor agonist with low addictive potential and dependence liability. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3609-3613.	1.0	16
52	Association between two µ-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Human Molecular Genetics, 2006, 15, 807-819.	1.4	155
53	Co-Morbidity of Infectious and Addictive Diseases in St. Petersburg and the Leningrad Region, Russia. European Addiction Research, 2006, 12, 12-19.	1.3	46
54	Association Between Alcoholism and ??-Amino Butyric Acid ??2 Receptor Subtype in a Russian Population. Alcoholism: Clinical and Experimental Research, 2005, 29, 493-498.	1.4	188

EDWIN E ZVARTAU

#	Article	IF	CITATIONS
55	Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. European Neuropsychopharmacology, 2005, 15, 219-225.	0.3	75
56	Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug and Alcohol Dependence, 2005, 79, 251-256.	1.6	46
57	Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology, 2005, 49, 167-178.	2.0	126
58	The onset of HIV infection in the Leningrad region of Russia: a focus on drug and alcohol dependence. HIV Medicine, 2004, 5, 30-33.	1.0	33
59	Effects of morphine and cocaine in mice with stable high aggressive and nonaggressive behavioral strategy. Pharmacology Biochemistry and Behavior, 2004, 77, 235-243.	1.3	16
60	Intravenous self-administration of abused solvents and anesthetics in mice. European Journal of Pharmacology, 2004, 485, 211-218.	1.7	57
61	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-183.	2.0	35
62	Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2004, 26, 285-294.	1.5	96
63	Effects of morphine on formalin-induced nociception in rats. European Journal of Pharmacology, 2003, 462, 109-113.	1.7	27
64	Facilitation of electrical brain self-stimulation behavior by abused solvents. Pharmacology Biochemistry and Behavior, 2003, 75, 199-208.	1.3	24
65	Altered Cardiovascular Responses to Nitrosorbide in Alcohol Withdrawal. Neuropsychobiology, 2003, 48, 124-130.	0.9	6
66	Syphilis among intravenous drug-using population: epidemiological situation in St Petersburg, Russia. International Journal of STD and AIDS, 2002, 13, 618-623.	0.5	30
67	A Pilot Study of Memantine Effects on Protracted Withdrawal (Syndrome of Anhedonia) in Heroin Addicts. Addictive Disorders and Their Treatment, 2002, 1, 143-146.	0.5	20
68	Behavioral analysis of the saccharin deprivation effect in rats Behavioral Neuroscience, 2002, 116, 747-756.	0.6	11
69	Endogenous digitalis-like ligands of the sodium pump: possible involvement in mood control and ethanol addiction. European Neuropsychopharmacology, 2002, 12, 1-12.	0.3	23
70	Marinobufagenin (MBG) suppression of ethanol-seeking behavior is associated with inhibition of brain cortex Na/K-ATPase in mice. European Neuropsychopharmacology, 2002, 12, 217-223.	0.3	12
71	Sweet liking and family history of alcoholism in hospitalized alcoholic and non-alcoholic patients. Alcohol and Alcoholism, 2001, 36, 165-170.	0.9	90
72	Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. Neuroscience and Biobehavioral Reviews, 2001, 25, 343-353.	2.9	36

#	Article	IF	CITATIONS
73	Analgesic effect of olipiphate on mouse model of chemical stimulation of peritoneum. Bulletin of Experimental Biology and Medicine, 2001, 131, 254-256.	0.3	1
74	Prevention of Suicide by Naltrexone in a Recently Detoxified Heroin Addict. European Addiction Research, 2001, 7, 87-88.	1.3	9
75	Effects of the NMDA receptor antagonist, d -CPPene, on sensitization to the operant decrement produced by naloxone in morphine-treated rats. Behavioural Pharmacology, 2001, 12, 135-142.	0.8	3
76	Effects of N -methyl-d-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behavioural Pharmacology, 2000, 11, 37-44.	0.8	46
77	Decrement in Operant Performance Produced by NMDA Receptor Antagonists in the Rat. Pharmacology Biochemistry and Behavior, 2000, 65, 611-620.	1.3	1
78	Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. European Journal of Pharmacology, 2000, 390, 303-311.	1.7	31
79	Co-housing in a stable hierarchical group is not aversive for dominant and subordinate individuals. Neuroscience and Behavioral Physiology, 2000, 30, 195-200.	0.2	16
80	Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice. European Neuropsychopharmacology, 2000, 10, 447-454.	0.3	18
81	Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. European Neuropsychopharmacology, 1999, 9, 377-383.	0.3	44
82	Involvement of endogenous digitalis-like factors involuntary selection of alcohol by rats. Life Sciences, 1999, 64, PL219-PL225.	2.0	15
83	Caffeine, acting on adenosine A(1) receptors, prevents the extinction of cocaine-seeking behavior in mice. Journal of Pharmacology and Experimental Therapeutics, 1999, 290, 535-42.	1.3	29
84	Nifedipine but not verapamil inhibits subjective effects of i.v. morphine in opiate-dependent patients. Addiction Biology, 1998, 3, 345-351.	1.4	1
85	Prolongation of morphine analgesia by competitive NMDA receptor antagonist d-CPPene (SDZ EAA 494) in rats. European Journal of Pharmacology, 1998, 351, 299-305.	1.7	29
86	Caffeine place conditioning in rats: comparison with cocaine and ethanol. European Neuropsychopharmacology, 1998, 8, 287-291.	0.3	45
87	κ-Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. European Journal of Pharmacology, 1997, 321, 265-271.	1.7	101
88	NMDA receptor antagonists prevent conditioned activation of intracranial self-stimulation in rats. European Journal of Pharmacology, 1997, 326, 109-112.	1.7	9
89	Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sciences, 1997, 60, PL257-PL264.	2.0	51
90	Enhancement of morphine self-administration in drug naive, inbred strains of mice by acute emotional stress. European Neuropsychopharmacology, 1996, 6, 63-68.	0.3	34

#	Article	IF	CITATIONS
91	Effect of isradipine, a dihydropyridine-calcium antagonist on I.V. self-administration of morphine in rats. Life Sciences, 1996, 59, PL159-PL164.	2.0	0
92	Modulation of cocaine intravenous self-administration in drug-naive animals by dihydropyridine Ca2+ channel modulators. European Journal of Pharmacology, 1996, 295, 19-25.	1.7	31
93	Effect of kinurenic acid on the acquisition of intravenous morphine self-administration habit by rats. Bulletin of Experimental Biology and Medicine, 1996, 122, 698-700.	0.3	2
94	Intraaccumbens administration of NMDA receptor antagonist (±)-CPP prevents locomotor activation conditioned by morphine and amphetamine in rats. Pharmacology Biochemistry and Behavior, 1996, 55, 203-207.	1.3	28
95	Classical conditioning of electrical self-stimulation of ventral tegmental area to brief visual stimuli in rats. Journal of Neuroscience Methods, 1996, 70, 1-4.	1.3	1
96	Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats. Psychopharmacology, 1995, 119, 92-98.	1.5	72
97	Strain differences in the analgesic and reinforcing action of morphine in mice. Pharmacology Biochemistry and Behavior, 1995, 50, 17-21.	1.3	64
98	Isradipine inhibits nicotine intravenous self-administration in drug-naive mice. Pharmacology Biochemistry and Behavior, 1995, 52, 271-274.	1.3	50
99	Behavioral effects of MK-801 in morphine-dependent and non-dependent mice. Life Sciences, 1995, 58, PL55-PL61.	2.0	2
100	Subchronic morphine increases amphetamine-induced potentiation of brain stimulation reward: reversal by DNQX. European Neuropsychopharmacology, 1995, 5, 89-93.	0.3	3
101	Tolerance for opiate analgesia: Complex effect of antagonists of receptors for excitatory amino acids. Bulletin of Experimental Biology and Medicine, 1994, 117, 491-493.	0.3	0
102	A comparison of the effects of individual organic solvents and their mixture on brain stimulation reward. Pharmacology Biochemistry and Behavior, 1994, 48, 661-664.	1.3	16
103	Studies of the analgesic activity of calcitonin fragments. Pharmaceutical Chemistry Journal, 1994, 28, 728-731.	0.3	0
104	Experimental estimation of addictive potential of a mixture of organic solvents. European Neuropsychopharmacology, 1994, 4, 111-118.	0.3	31
105	Analgesic and reinforcing effects of morphine in mice. Influence of Bay K-8644 and nimodipine. Brain Research, 1994, 652, 1-8.	1.1	24
106	Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. European Journal of Pharmacology, 1994, 264, 233-239.	1.7	56
107	Calcium entry blockers and drug addiction. European Neuropsychopharmacology, 1993, 3, 220-221.	0.3	1
108	Isradipine is able to separate morphine-induced analgesia and place conditioning. Brain Research, 1992, 593, 221-225.	1.1	22

#	Article	lF	CITATIONS
109	Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice. Pharmacology Biochemistry and Behavior, 1992, 41, 497-500.	1.3	96
110	Simple methodology of assessment of analgesics' addictive potential in mice. Pharmacology Biochemistry and Behavior, 1991, 39, 873-876.	1.3	24
111	Synthesis of 8-arylmorphones and 8-arylcodones and study of their analgesic activity. Pharmaceutical Chemistry Journal, 1989, 23, 44-46.	0.3	0
112	Neuroanatomical dissociation between reinforcing and analgesic effects of morphine. Bulletin of Experimental Biology and Medicine, 1989, 107, 53-55.	0.3	0
113	The reinforcing but nonanalgesic action of opioid stimulation of the ventral tegmental area. Bulletin of Experimental Biology and Medicine, 1986, 102, 1065-1068.	0.3	2
114	Characteristics of brain and spinal cord opiate receptors in morphine-tolerant mice. Bulletin of Experimental Biology and Medicine, 1986, 102, 1209-1211.	0.3	0
115	Stimulation-produced analgesia under repeated morphine treatment in rats. Pharmacology Biochemistry and Behavior, 1986, 25, 533-536.	1.3	3
116	Influence on the emotional reinforcing systems of the brain as a method of pathogenetic therapy of alcoholism and toxicomania. Neuroscience and Behavioral Physiology, 1985, 15, 17-21.	0.2	0
117	Comparison of the discriminative and analgesic effects of morphine. Bulletin of Experimental Biology and Medicine, 1984, 98, 1538-1540.	0.3	0
118	Systems of reinforcement and drug dependence. Drug and Alcohol Dependence, 1982, 10, 295-301.	1.6	8
119	Action of naloxone on emotionally positive and antinociceptive effects of hypothalamic stimulation in rats. Bulletin of Experimental Biology and Medicine, 1979, 88, 1306-1309.	0.3	1
120	Hypothalamic self-stimulation in morphine-dependent rats during the abstinence syndrome. Bulletin of Experimental Biology and Medicine, 1978, 85, 321-324.	0.3	1
121	Role of the monoamines on positive and negative reinforcing systems of the brain. Annali Dell'Istituto Superiore Di Sanita, 1978, 14, 59-62.	0.2	0
122	Hypothalamic self-stimulation under the chronic morphine treatment in the rat. Research Communications in Chemical Pathology and Pharmacology, 1977, 16, 707-19.	0.2	1
123	Motivational properties of hypothalamic stimulation in cats. Bulletin of Experimental Biology and Medicine, 1973, 75, 233-235.	0.3	1
124	Effect of amphetamine and amytal sodium on blood serotonin level during stimulation of the hypothalamus. Bulletin of Experimental Biology and Medicine, 1971, 71, 523-524.	0.3	0